The François Jacob Institute of Biology brings together five departments and three services
The last two years in scientific news
Scientific result | Brain | Neurodegenerative diseases | Gene and cell therapy
A study carried out in a primate model of Huntington's disease and involving several European research organisms1, including MIRCen (François Jacob Institute of Biology, CEA) and the Inserm/UEVE UMR861 group (Institute for Stem cell Therapy and Exploration of Monogenic Diseases, AFM-Téléthon), has shown that generating neuronal grafts with high recipient histocompatibility , a cell therapy for certain neurodegenerative diseases, was not sufficient to eliminate the need for immunosuppressive treatments and their consequential adverse effects. The work provides important information for the clinical translation of cell therapies in the setting of neurodegenerative disorders.
Cell therapies2 hold promise in the development of treatments for neurodegenerative pathologies such as Huntington's disease. In such disorders, cell therapy may take the form of neuronal grafts in the brains of patients. Toward that goal, human pluripotent stem cells offer the advantages of renewability and specific differentiability into healthy and transplantable neurons potentially capable of alleviating and even eliminating symptoms in the graft recipient.
MHC matching fails to prevent long-term rejection of iPSC-derived neurons in non-human primates, Nature Communications volume 10, Article number: 4357 (2019) Romina Aron-Badin et al.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.